Patent protection of ONCOS-102 in combination with
chemotherapy in malignant pleural mesothelioma in Europe
OSLO, Norway, Sept. 24, 2021 /PRNewswire/ -- Targovax ASA
(OSE: TRVX), a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors, today
announce that the European Patent Office has granted EU Patent no
EP3402889. The patent covers the use of ONCOS-102 in combination
with chemotherapy in malignant pleural mesothelioma.
Torbjørn Furuseth, Chief Financial Officer of Targovax, said:
"We are delighted that this EU patent has been granted, further
strengthening Targovax's intellectual property portfolio. The
24-month data from our ONCOS-102 trial in mesothelioma demonstrates
encouraging survival data in this area of large medical need.
Securing this patent protects our innovative oncolytic
immunotherapy platform and strengthens our future market
position."
Targovax's lead product candidate, ONCOS-102, is a genetically
modified oncolytic adenovirus, which has been engineered to
selectively infect cancer cells and activate the immune system. In
June 2021, the 24-month follow-up in
the malignant pleural mesothelioma (MPM) trial showed that median
overall survival (mOS) for patients in first-line treatment with
ONCOS-102 plus chemotherapy will be between 21.9 and 25.0 months,
which is very encouraging in this patient population. For the
first-line standard of care (SoC)-only control group mOS is 13.5
months, which is similar to outcomes from previously reported
trials where patients received the same chemotherapy treatment. In
this open label phase I/II trial, ONCOS-102 has been tested in
first and second (or later) line MPM patients to assess safety,
immune activation, and clinical efficacy of the combination of
ONCOS-102 to SoC chemotherapy (pemetrexed/cisplatin).
Based on these encouraging pre-clinical and clinical effects
associated with broad immune activation, the US FDA granted
ONCOS-102 Fast Track designation for MPM in February 2021. Targovax has previously received
orphan drug designation for MPM in both the US FDA and the European
Medicines Agency.
For further information, please contact:
Oystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-granted-european-patent-for-oncos-102-in-combination-with-chemotherapy,c3421092